Literature DB >> 25228120

A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence.

Clément François1, Philippe Laramée, Nora Rahhali, Ylana Chalem, Samuel Aballéa, Aurélie Millier, Sébastien Bineau, Mondher Toumi, Jürgen Rehm.   

Abstract

BACKGROUND: Alcohol consumption is one of the most important factors for disease and disability in Europe. In clinical trials, nalmefene has resulted in a significant reduction in the number of heavy-drinking days (HDDs) per month and total alcohol consumption (TAC) among alcohol-dependent patients versus placebo.
METHODS: A microsimulation model was developed to estimate alcohol-attributable diseases and injuries in patients with alcohol dependence and to explore the clinical relevance of reducing alcohol consumption.
RESULTS: For all diseases and injuries considered, the number of events (inpatient episodes) increased with the number of HDDs and TAC per year. The model predicted that a reduction of 20 HDDs per year would result in 941 fewer alcohol-attributable events per 100,000 patients, while a reduction in intake of 3,000 g/year of pure alcohol (ethanol) would result in 1,325 fewer events per 100,000 patients.
CONCLUSION: The potential gains of reducing consumption in alcohol-dependent patients were considerable.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25228120     DOI: 10.1159/000362408

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  6 in total

1.  Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Authors:  Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2018-11-05       Impact factor: 3.455

2.  Modelling the consequences of a reduction in alcohol consumption among patients with alcohol dependence based on real-life observational data.

Authors:  Nora Rahhali; Aurélie Millier; Benjamin Briquet; Philippe Laramée; Samuel Aballéa; Mondher Toumi; Clément François; Jürgen Rehm; Jean-Bernard Daeppen
Journal:  BMC Public Health       Date:  2015-12-21       Impact factor: 3.295

Review 3.  Risk of All-Cause Mortality in Alcohol-Dependent Individuals: A Systematic Literature Review and Meta-Analysis.

Authors:  Philippe Laramée; Saoirse Leonard; Amy Buchanan-Hughes; Samantha Warnakula; Jean-Bernard Daeppen; Jürgen Rehm
Journal:  EBioMedicine       Date:  2015-09-02       Impact factor: 8.143

Review 4.  "Doctor, Can I Drink an Alcohol-Free Beer?" Low-Alcohol and Alcohol-Free Drinks in People with Heavy Drinking or Alcohol Use Disorders: Systematic Review of the Literature.

Authors:  Elsa Caballeria; Maria Teresa Pons-Cabrera; Mercedes Balcells-Oliveró; Fleur Braddick; Rebecca Gordon; Antoni Gual; Silvia Matrai; Hugo López-Pelayo
Journal:  Nutrients       Date:  2022-09-22       Impact factor: 6.706

Review 5.  Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.

Authors:  Niamh Fitzgerald; Kathryn Angus; Andrew Elders; Marisa de Andrade; Duncan Raistrick; Nick Heather; Jim McCambridge
Journal:  Addiction       Date:  2016-06-05       Impact factor: 6.526

6.  Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk.

Authors:  Michael Roerecke; Per Sørensen; Philippe Laramée; Nora Rahhali; Jürgen Rehm
Journal:  J Psychopharmacol       Date:  2015-09-08       Impact factor: 4.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.